Evidence map›Paper›PMID 26743756›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2016

Preparation and evaluation of reduction-responsive nano-micelles for miriplatin delivery.

Ying Zhang, Dejian Hu, Shangcong Han, Guowen Yan, Chao Ma, Chen Wei, Miao Yu, Dongmei Li, Yong Sun

Abstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ying ZhangDepartment of pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China.
Dejian HuWeifang People's Hospital, Weifang 261041, China.
Shangcong HanDepartment of pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China.
Guowen YanDepartment of pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China.
Chao MaDepartment of pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China.
Chen WeiDepartment of pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China.
Miao YuDepartment of pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China.
Dongmei LiAffiliated Hospital of Qingdao University, Qingdao 266071, China The first two authors contributed equally to this work. ldmdrug@163.com sunyongqdu@163.com.
Yong SunDepartment of pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A reduction-responsive amphiphilic core-shell micelle for miriplatin delivery was prepared and evaluated. A pyrene-terminated poly(2-(dimethylamino) ethyl acrylate) was synthesized through reversible addition-fragmentation chain transfer polymerization with 4-cyano-4-(ethylthiocarbonothioylthio) pentanoic acid as reversible addition-fragmentation chain transfer reagent and further modified by 2,2'-dithiodiethanol and 1-pyrenebutyric acid. Self-assembled blank micelles and drug-loaded micelles were obtained by dialysis method, and the particle size was proved to be about 40 nm with narrow dispersity by dynamic laser light scattering. Morphology results showed that blank micelles and drug-loaded micelles were spherical nanoparticles confirmed by transmission electron microscope, and the critical micelle concentration was as low as 6.09 µg/mL via pyrene fluorescence probe method. The reductive sensitivity of disulfide bond in BMs was further verified by changes in particle size, pyrene fluorescence intensity ratio (I338/I333), and morphology after treatment by dithiothreitol. Moreover, drug release rate in vitro of drug-loaded micelles was evaluated and the results suggested that this amphiphilic pyrene-modified poly(2-(dimethylamino) ethyl acrylate) can be used as reduction-triggered controlled release drug delivery carrier for hydrophobic drug.

Indexed as

MicellesNanoparticlesDisulfidesDithiothreitolDrug CarriersMicroscopy, Electron, TransmissionOrganoplatinum CompoundsOxidation-ReductionDisulfidesDithiothreitolDrug CarriersMicellesmiriplatinOrganoplatinum Compoundsdrug deliverymiriplatinnano-micellepassive targetingReduction-responsive

Identifiers

PMID26743756
PMCPMC4950310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.